Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTCYNASDAQ:ICUNASDAQ:PAVMNASDAQ:VERO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTCYBiotricity$0.48+16.9%$0.44$0.19▼$1.30$12.00M1.2237,022 shs28,069 shsICUSeaStar Medical$1.24$1.50$1.11▼$13.85$12.16M-0.9263,507 shs106,847 shsPAVMPAVmed$0.65+3.0%$0.71$0.55▼$1.96$11.09M1.11122,327 shs178,128 shsVEROVenus Concept$2.20-0.9%$3.04$2.10▼$17.49$3.13M-0.03384,643 shs81,163 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTCYBiotricity0.00%-5.53%+14.71%+12.05%-57.74%ICUSeaStar Medical0.00%-0.80%-0.80%-30.73%-85.48%PAVMPAVmed0.00%-2.79%-8.59%-17.85%-65.84%VEROVenus Concept0.00%-8.71%-23.88%-39.70%-70.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTCYBiotricityN/AN/AN/AN/AN/AN/AN/AN/AICUSeaStar Medical0.5604 of 5 stars0.05.00.00.02.00.00.0PAVMPAVmed4.1632 of 5 stars3.54.00.04.33.20.00.6VEROVenus Concept0.6232 of 5 stars0.02.00.00.02.03.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTCYBiotricity 2.00HoldN/AN/AICUSeaStar Medical 0.00N/AN/AN/APAVMPAVmed 3.00Buy$19.502,904.62% UpsideVEROVenus Concept 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VERO, BTCY, ICU, and PAVM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025PAVMPAVmedAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $19.50(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTCYBiotricity$12.06M0.99N/AN/A($1.30) per share-0.37ICUSeaStar Medical$135K90.04N/AN/A($6.29) per share-0.20PAVMPAVmed$3.00M3.70N/AN/A($3.35) per share-0.19VEROVenus Concept$64.83M0.05N/AN/A($2.43) per share-0.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTCYBiotricity-$14.09M-$1.08N/A∞N/A-80.42%N/A-188.47%6/25/2025 (Estimated)ICUSeaStar Medical-$26.23M-$3.47N/A∞N/AN/AN/A-627.49%N/APAVMPAVmed-$64.18M$0.71N/AN/AN/A602.97%N/A-92.36%N/AVEROVenus Concept-$37.25M-$77.35N/A∞N/A-74.62%N/A-47.46%N/ALatest VERO, BTCY, ICU, and PAVM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025VEROVenus ConceptN/A-$17.44N/A-$17.44N/A$13.64 million5/14/2025Q1 2025ICUSeaStar Medical-$0.52-$0.44+$0.08-$0.44$0.15 million$0.29 million3/31/2025Q4 2024VEROVenus Concept-$10.0089-$11.23-$1.2211-$11.23$16.99 million$15.77 million3/27/2025Q4 2024ICUSeaStar Medical-$0.89-$0.90-$0.01-$0.90$0.15 million$0.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTCYBiotricityN/AN/AN/AN/AN/AICUSeaStar MedicalN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/AVEROVenus ConceptN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTCYBiotricityN/A0.230.10ICUSeaStar MedicalN/A0.540.54PAVMPAVmedN/A0.060.06VEROVenus Concept2.831.861.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTCYBiotricity3.89%ICUSeaStar Medical1.69%PAVMPAVmed19.93%VEROVenus Concept87.41%Insider OwnershipCompanyInsider OwnershipBTCYBiotricity10.10%ICUSeaStar Medical1.30%PAVMPAVmed7.30%VEROVenus Concept28.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTCYBiotricity4024.91 million22.08 millionOptionableICUSeaStar Medical29.80 million4.37 millionNot OptionablePAVMPAVmed9017.09 million9.82 millionOptionableVEROVenus Concept4101.42 million3.70 millionNot OptionableVERO, BTCY, ICU, and PAVM HeadlinesRecent News About These CompaniesVenus Concept Announces First Quarter 2025 Financial ResultsMay 16 at 2:24 PM | theglobeandmail.comVenus Concept Inc (VERO) Q1 2025 Earnings Call Highlights: Navigating Revenue Declines Amid ...May 16 at 2:24 PM | finance.yahoo.comVenus Concept Inc. (NASDAQ:VERO) Q1 2025 Earnings Call TranscriptMay 16 at 2:24 PM | msn.comVenus Concept Inc. (VERO) Q1 2025 Earnings Call TranscriptMay 15 at 11:14 AM | seekingalpha.comVenus Concept Raises a Total of Approximately $2.7 Million in Gross Proceeds from Previously Announced Registered Direct Offerings of Common StockApril 14, 2025 | globenewswire.comVenus Concept prices 386,700 shares at $4.06 in registered direct offeringApril 11, 2025 | markets.businessinsider.comVenus Concept Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesApril 11, 2025 | globenewswire.comVenus Concept Announces Closing of $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesApril 10, 2025 | globenewswire.comVenus Concept to sell 328,573 shares at $3.50 in registered direct offeringApril 9, 2025 | markets.businessinsider.comVenus Concept Shares Tripled On Wednesday: Here's What HappenedApril 9, 2025 | benzinga.comVenus Concept Announces $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesApril 9, 2025 | globenewswire.comVenus Concept Announces $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesApril 9, 2025 | globenewswire.comVenus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025April 7, 2025 | globenewswire.comVenus Concept announces $11M debt-to-equity exchange transactionApril 2, 2025 | markets.businessinsider.comVenus Concept Completes Debt-to-Equity Exchange with MadrynApril 2, 2025 | tipranks.comVenus Concept Announces $11 million Debt-to-Equity Exchange TransactionApril 1, 2025 | globenewswire.comVenus Concept Inc. (NASDAQ:VERO) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comVenus Concept reports Q4 EPS ($11.23) vs ($20.14) last yearApril 1, 2025 | markets.businessinsider.comVenus concept signals revenue stabilization as strategic shifts concludeMarch 31, 2025 | msn.comVenus Concept Inc. (VERO) Q4 2024 Earnings Conference Call TranscriptMarch 31, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumTop Analyst-Rated Healthcare Stocks to Watch NowBy Nathan Reiff | May 11, 2025View Top Analyst-Rated Healthcare Stocks to Watch NowNetflix’s Trillion-Dollar Baby Ambition: Realistic or Ridiculous?By Leo Miller | April 24, 2025View Netflix’s Trillion-Dollar Baby Ambition: Realistic or Ridiculous?3 High-Momentum Gold Stocks Surging on the Metals RallyBy Nathan Reiff | April 30, 2025View 3 High-Momentum Gold Stocks Surging on the Metals RallyVERO, BTCY, ICU, and PAVM Company DescriptionsBiotricity NASDAQ:BTCY$0.48 +0.07 (+16.94%) As of 05/16/2025 01:04 PM EasternBiotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.SeaStar Medical NASDAQ:ICU$1.24 0.00 (0.00%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$1.25 +0.01 (+0.40%) As of 05/16/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.PAVmed NASDAQ:PAVM$0.65 +0.02 (+3.03%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$0.65 +0.00 (+0.15%) As of 05/16/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.Venus Concept NASDAQ:VERO$2.20 -0.02 (-0.90%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$2.13 -0.07 (-3.14%) As of 05/16/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Savvy Investors Are Raising a Glass for Heineken Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
